AF
DNTH icon

Amalgamated Financial’s Dianthus Therapeutics DNTH Stock Holding History

Amalgamated Financial’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$14K Buy
+296
New +$16.2K ﹤0.01% 2830

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Amalgamated Financial's DNTH Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Dianthus Therapeutics (DNTH) in Q1 2022: 296 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2830 among its holdings.

93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

  • Amalgamated Financial held 296 shares of Dianthus Therapeutics worth $14K as of Q1 2022.
  • Dianthus Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Dianthus Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2830 holding.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.